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a  b  s  t  r  a  c  t
In  12  of  13 phase  3 and  4 comparative  clinical  trials,  all-cause  mortality  was  higher  in  the  tigecycline  group
versus  the  comparator  group.  Study-level  mortality  risk  differences  were  pooled  using  a  random-effects
meta-analysis.  Statistical  models  evaluated  the  association  between  patient-level  all-cause  mortality
and  baseline  factors  using  logistic  regression,  recursive  partitioning  [classiﬁcation  and  regression  tree
(CART)  analysis]  and  survival  techniques.  The  estimated  risk  difference  (tigecycline  minus  comparator)ortality
ll-cause
lycylcycline
eta-analysis
atient-level data
in all-cause  mortality  from  the meta-analysis  was  0.6%  (95%  conﬁdence  interval  0.1–1.2%).  Statistical
modelling  identiﬁed  baseline  bacteraemia  associated  with  mortality  only  in  the  tigecycline  group.  In
patients  with  ventilator-associated  pneumonia  (VAP)  and  baseline  bacteraemia,  mortality  was  50.0%
(9/18)  for  tigecycline  versus  7.7%  (1/13)  for  the  comparator  group.  Study-level  and  patient-level  analyses
have identiﬁed  that  patients  in  the  hospital-acquired  pneumonia  trial,  particularly  those  with  VAP with
baseline  bacteraemia,  were  at a higher  risk  of clinical  failure  and  mortality.. Introduction
Tigecycline is a glycylcycline antibiotic that was  devel-
ped to restore the broad spectrum of activity and clinical
tility to the tetracycline class of antibiotics. The tigecycline
linical development programme investigated the efﬁcacy and
afety of tigecycline in hospitalised patients with serious infec-
ions. Tigecycline is approved for the treatment of complicated
kin and skin-structure infections, complicated intra-abdominal
nfections (cIAIs) and community-acquired pneumonia (CAP).
owever, tigecycline did not meet the primary endpoints in
ospital-acquired pneumonia (HAP) and diabetic foot infection
rials.
An unexpected observation was the numerical increase in all-
ause mortality in tigecycline-treated patients in phase 3 and 4
linical trials [1].  Recently, several independent meta-analyses on
igecycline all-cause mortality have been published, all of which
ere based on study-level data only [2–5]. This article is the ﬁrst
o present patient-level data that would be helpful to better under-
tand these ﬁndings [4].∗ Corresponding author. Tel.: +1 484 865 2010; fax: +1 484 865 4355.
E-mail address: paul.mcgovern@pﬁzer.com (P.C. McGovern).
924-8579     ©  2013 Elsevier B.V. and the International Society of Chemotherapy.
ttp://dx.doi.org/10.1016/j.ijantimicag.2013.01.020
Open a© 2013 Elsevier B.V. and the International Society of Chemotherapy. 
2. Materials and methods
2.1. Studies
Tigecycline was  studied in 14 phase 3 and 4 trials between
August 2001 and September 2008, including 13 comparative stud-
ies. The study design, comparator and number of patients treated
have been accurately reported elsewhere [2];  however, six addi-
tional patients (two tigecycline, four comparator) were included in
our analysis to capture all patients who died.
2.2. Patient population
Unless otherwise noted, these analyses were based on the
modiﬁed intention-to-treat (safety) population, which includes all
patients who  were randomised and received at least one dose of
study medication.
2.3. Risk factors
Demographic and baseline variables examined as potential
Open access under CC BY-NC-ND license. factors that could affect mortality included age, co-morbidities,
mortality prediction scores [Acute Physiology and Chronic Health
Evaluation (APACHE) II score where available], infection type,
prior antibiotic failure, baseline pathogen and minimum inhibitory
 ccess under CC BY-NC-ND license. 
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Table 1
Demographic and baseline characteristics in the modiﬁed intention-to-treat population.
Characteristica P valueb Mortality subgroup
Died Survived
Tigecycline (n = 150) Comparator (n = 110) Tigecycline (n = 3638) Comparator (n = 3536)
Age (years) (mean) 0.630f 65.96 66.90 50.96 50.71
Male  sex [n (%)] 0.698g 91 (60.7) 70 (63.6) 2303 (63.3) 2288 (64.7)
APACHE II score (mean)c 0.864f 13.43 13.57 7.39 7.36
Baseline albumin (g/L) (mean)d 0.953f 25.38 25.44 34.45 34.58
Alkaline phosphatase (U/L) (mean) 0.301f 155.62 140.11 125.11 123.45
Creatinine (mol/L) (mean)e 0.906f 97.32 98.05 85.30 85.62
WBC  (109/L) (mean) 0.023f 12.79 14.98 15.21 12.34
History of diabetes [n (%)] 0.246g 42 (28.0) 23 (20.9) 1013 (27.8) 940 (26.6)
COPD  [n (%)] 0.254g 23 (15.3) 23 (20.9) 154 (4.2) 145 (4.1)
CHF  [n (%)] 0.603g 21 (14.0) 18 (16.4) 129 (3.5) 119 (3.4)
Prior  antibiotic failure [n (%)] 0.775g 37 (24.7) 29 (26.4) 605 (16.6) 533 (15.1)
Total  protein (g/L) (mean) 0.363f 54.47 55.89 65.95 65.83
BMI  (mean) 0.530f 25.05 25.60 26.79 26.72
APACHE, Acute Physiology and Chronic Health Evaluation; WBC, white blood cells; COPD, chronic obstructive pulmonary disease; CHF, congestive heart failure; BMI, body
mass  index.
a Baseline information was not available for all patients. There was no imputation for missing values.
b P-values represent comparisons between incidences of tigecycline deaths and comparator deaths.
c Not all studies collected APACHE II score data.
d Albumin level was not collected in the phase 4 trials.
e To convert to mg/dL, divide by 88.4.
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of One-way analysis of variance with treatment as factor.
g Fisher’s exact test P-value (two-tailed).
oncentrations (MIC), baseline concomitant bacteraemia and base-
ine laboratory data.
.4. Statistical methods
A  DerSimonian and Laird random-effects model meta-analysis
6], with trial as the random effect, was used to estimate an overall
isk difference and 95% conﬁdence interval (CI). The risk difference
as chosen as the most meaningful quantity from a public health
erspective. Logistic regression and classiﬁcation and regression
ree (CART) models were used to explore the inﬂuence and relative
trength of various predictors on mortality. From separate logistic
egression models for tigecycline-treated patients and comparator-
reated patients, 2 minus degrees of freedom statistics were used
o assess the relative importance of individual predictors. Larger
alues implied greater importance. Kaplan–Meier survival curves
ere used to qualitatively examine the relative timing of events.
nless otherwise noted, statistical signiﬁcance refers to a two-sided
ype 1 error of 0.05. Computations were carried out in R v.2.10 lan-
uage and supplemental libraries (http://www.R-project.org) and
AS v.9.2 (SAS Institute Inc., Cary, NC).
. Results
.1. Study-level results
In the 13 phase 3 and 4 comparative studies, 4.0% (150/3788)
f tigecycline-treated patients and 3.0% (110/3646) of comparator-
reated patients died. In a pooled analysis of these trials, based on
 random-effects model by trial weight, the adjusted risk differ-
nce for all-cause mortality was 0.6% (95% CI 0.1–1.2%) between
igecycline-treated patients and comparator-treated patients. The
0-day all-cause mortality was 3.2% and 2.6% in tigecycline-treated
atients and comparator-treated patients, respectively (adjusted
isk difference 0.4, 95% CI −0.1 to 0.9). There were no statistically
igniﬁcant differences between treatment groups by infection type
7]. The highest mortality rates in tigecycline-treated patients were
bserved in the ventilator-associated pneumonia (VAP) subgroupof the HAP trial (19.1%) and in the Resistant Pathogen (RP) 307 trial
(8.6%).
3.2. Baseline demographics
Baseline demographics of patients who  did and did not die in
each treatment group are presented in Table 1. The data presented
are representative of risk factors of potential importance for mor-
tality and evaluated in the multivariate analyses. Differences in
baseline characteristics were observed between patients who died
and those who did not die; however, for most characteristics, the
tigecycline and comparator treatment groups were similar. In gen-
eral, patients who  died were older, had higher APACHE II scores,
lower albumin levels and higher creatinine levels. A greater number
of tigecycline-treated patients versus comparator-treated patients
with diabetes died, but the difference was not statistically signif-
icant. Baseline white blood cell values were statistically lower in
tigecycline-treated patients who died; however, the clinical signif-
icance of the difference is unclear.
3.3. Baseline pathogens
Baseline pathogens and MICs were examined in patients who
died. The frequencies of patients who  died without a known
baseline pathogen were similar between the tigecycline (30.7%)
and comparator (30.9%) treatment groups. More comparator-
treated patients died with baseline isolates of Acinetobacter
calcoaceticus/baumannii (10.0% vs. 6.0%), Pseudomonas aeruginosa
(9.1% vs. 7.3%) and meticillin-sensitive Staphylococcus aureus (13.6%
vs. 8.7%), whilst a greater number of tigecycline-treated patients
with baseline isolates of Escherichia coli (17.3% vs. 13.6%), Kleb-
siella pneumoniae (14.7% vs. 9.1%) and meticillin-resistant S. aureus
(12.0% vs. 9.1%) died. Overall, the tigecycline MIC90 (MIC that
inhibited growth of 90% of strains) for pathogens except P.
aeruginosa was ≤1.0 g/mL for tigecycline-treated patients. The
MIC90 for K. pneumoniae in patients who died was 1.0 g/mL;
however, the MIC90 was  2.0 g/mL in patients with HAP who
died.
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none of these patients were receiving tigecycline for an approved
indication. Moreover, 7 (50.0%) of 14 HAP patients treated with tige-
cycline and 2 (28.6%) of 7 RP 307 patients treated with tigecycline
Table 2
Mortality in patients with baseline bacteraemia by infection type in the modiﬁed
intention-to-treat population.a
Tigecycline [n (%)]b Comparator [n (%)]b
Approved indications
cSSSI 2/28 (7.1) 1/31 (3.2)
cIAI 4/75 (5.3) 5/58 (8.6)
CAP 1/35 (2.9) 1/31 (3.2)
Non-approved indications
HAP 14/44 (31.8) 6/42 (14.3)
Non-VAP 5/26 (19.2) 5/29 (17.2)
VAP 9/18 (50.0) 1/13 (7.7)
RP 307 7/25 (28.0) 2/9 (22.2)
cSSSI, complicated skin and skin-structure infection; cIAI, complicated intra-ig. 1. Classiﬁcation and regression tree (CART) analysis shows signiﬁcant predi
ssociated with speciﬁc factor ranges (continuous variables) or levels (categorical v
ospital-acquired pneumonia; APACHE II, Acute Physiology and Chronic Health Eva
.4. Survival analyses
Kaplan–Meier analyses were performed for the 13 studies
ooled (data not shown) and a large separation occurred after 40
ays. Kaplan–Meier analyses by indication suggested differences
n the risk of death among indications, with the highest risk (i.e.
reater slope) in the HAP and RP 307 studies.
A categorical distribution of the timing of death relative to both
he ﬁrst and last dose was also performed. Death within 2 days
5.3% vs. 6.4%) and within 7 days (20.7% vs. 21.8%) of ﬁrst dose
as similar between the tigecycline and comparator-treatment
roups, respectively. The greatest early difference between the tige-
ycline and comparator groups occurred between Days 8 and 14,
ith 29.3% and 26.6% of deaths, respectively. More tigecycline-
reated patients died ≥15 days after the last dose of therapy (28.7%
s. 22.7% for comparator-treated patients) and more tigecycline-
reated patients in this group of late deaths were deemed a clinical
ure at the test-of-cure visit by the investigators (8.7% vs. 2.7% for
omparator-treated patients). A review of late deaths revealed mul-
iple aetiologies and not late deaths owing to the primary infection
nder study.
.5. Risk factor analyses
Logistic regression analyses and CART modelling each identi-
ed a similar set of risk factors. Fig. 1 shows the CART model
ith potential predictors of mortality for all patients in the tigecy-
line trials. Low albumin, baseline bacteraemia, low total protein,
atients with HAP, older age, higher APACHE II score and prior
ntibiotic failure were associated with mortality. For example, in
he CART branch in bold in Fig. 1, 29 patients with low albumin lev-
ls (range 7.0–24.1 g/L), baseline bacteraemia and low total protein
range 27.0–45.0 g/L) were associated with a probability of death of
.59. Treatment assignment did not emerge as a risk factor in either
he CART modelling or logistic regression analyses (P = 0.3746) of
he pooled data.
A review of APACHE II scores by indication did not reveal lower
linical efﬁcacy in tigecycline-treated patients with a higher prob-
bility of mortality, with the exception of patients with VAP. In
he cIAI phase 3 and 4 trials, tigecycline cured 20/29 patients
69.0%) with APACHE II scores >15 in the clinically evaluable pop-
lation compared with 19/32 (59.4%) comparator-treated patients.
n the HAP trial, cure rates in patients with APACHE II scores
15 were 29/58 (50.0%) and 36/57 (63.2%) for the tigecycline and
mipenem/cilastatin regimens, respectively, with greater disparity
n clinical success in patients with VAP (36.0% vs. 58.3%). Finally, in
he RP 307 trial, 3/7 (42.9%) tigecycline-treated patients and 2/4ith the predicted probability of mortality (PM) and with number of deaths (n)
es). Albumin normal range, 35–55 g/L; total protein normal range, 55–80 g/L. HAP,
n II scoring system.
(50.0%) vancomycin-treated patients with APACHE II scores >15
were cured. Fine score was  not modelled; however, in patients with
CAP, tigecycline cured 55/62 patients (88.7%) with Fine scores of
IV–V in the clinically evaluable population compared with 51/65
(78.5%) levoﬂoxacin-treated patients.
Logistic regression models also were developed separately for
tigecycline-treated patients and comparator-treated patients. Rank
ordering of identiﬁed risk factors showed similarities between
treatment groups, with baseline bacteraemia identiﬁed as a factor
of greater importance in the tigecycline treatment group (Fig. 2).
A review of baseline bacteraemia by indication revealed similar
incidences of death between treatment groups in patients with
baseline bacteraemia in all infection types, except for patients in
the VAP subgroup of the HAP trial (Table 2). In the approved indi-
cations, 5.1% of tigecycline-treated and 5.8% of comparator-treated
patients with baseline bacteraemia died.
Persistent bacteraemia, deﬁned as blood cultures positive
after 24 h of therapy, was more common in tigecycline-treated
patients [8].  Overall, 25 tigecycline-treated patients and 9
comparator-treated patients had persistent bacteraemia; persis-
tent bacteraemia in the approved indications occurred in 6 patients
treated with tigecycline (24.0%) and 3 patients treated with com-
parator (33.3%). Among patients with baseline bacteraemia who
subsequently died, 9 tigecycline-treated patients (32.1%) and 1
comparator-treated patient (6.7%) also had persistent bacteraemia;abdominal infection; CAP, community-acquired pneumonia; HAP, hospital-
acquired pneumonia; VAP, ventilator-associated pneumonia; RP, resistant
pathogen.
a No patients with baseline bacteraemia died in the diabetic foot infection study.
b Percentages are based on total number of patients with bacteraemia at baseline.
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Fig. 2. Potential predictors of mortality based on logistic regression modelling based on 10 randomised trials (the 315 and 400 complicated intra-abdominal infection trials
and  the 900 complicated skin and skin-structure infection trial did not collect albumin levels and were not utilised in this analysis). Larger values imply greater importance.
Sensitivity analyses including all 13 trials did not alter the potential predictors identiﬁed. Sensitivity analysis using the seven trials collecting Acute Physiology and Chronic
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Dealth  Evaluation (APACHE) II score data identiﬁed this as a potential predictor both
eart  failure; COPD, chronic obstructive pulmonary disease; MRSA, meticillin-resis
ureus;  AST, aspartate aminotransferase; WBC, white blood cells.
ith baseline bacteraemia who subsequently died also had persis-
ent bacteraemia. Both of the RP 307 patients were treated with
igecycline for primary bacteraemia as opposed to secondary bac-
eraemia in the other clinical trials.
. Discussion
Study-level and patient-level analyses of clinical trial data were
nitiated by the sponsor (Pﬁzer Inc) to understand better the all-
ause mortality difference identiﬁed in the tigecycline clinical trial
rogramme [1].  The risk difference did not appear to be the con-
equence of treatment of a particular infection type based on
ensitivity analyses conducted to assess the inﬂuence of individ-
al studies and infection types on the overall results; however,
he HAP trial and the RP 307 trial accounted for 52% of all deaths,
espite having contributed only 15% of patients to the pooled
nalysis.
Patient-level analyses identiﬁed several risk factors traditionally
ssociated with higher mortality; however, baseline bacteraemia
as an important risk factor only in the tigecycline treatment
roup. Analysis by indication demonstrated that baseline bacter-
emia was important in the subgroup of patients with VAP but not
n the approved indications, which is consistent with a previous
nalysis [8].  Persistence of bacteraemia owing to low tigecycline
erum concentrations, higher bacterial load in HAP patients and
rimary bacteraemia, and/or insufﬁcient dose (discussed below)
echanistically may  explain the excess risk of death in the subset
f tigecycline patients with baseline bacteraemia.
Importantly, baseline pathogen and treatment assignment did
ot emerge as a risk factor in the patient-level analyses, whereas
nfection type (or indication) was an important risk factor for mor-
ality. This suggests that the association between treatment and
ortality is weaker than the association with other factors such as
nfection type.
The area under the concentration–time curve (AUC)/MIC ratio is
urrently the best pharmacodynamic predictor of tigecycline efﬁ-
acy [9,10].  Mean AUC and median-free AUC/MIC were decreased
n patients with VAP relative to those without VAP [11]. It has
een speculated that an insufﬁcient dose of tigecycline and increas-
ng pathogen MIC  may  have contributed to the lower efﬁcacy and
xcess mortality observed in the VAP subgroup of the HAP trial.
ata from a recent phase 2 HAP trial exploring higher doses ofecycline and comparator treatment groups. BMI, body mass index; CHF, congestive
taphylococcus aureus; ALT, alanine aminotransferase; MSSA, meticillin-sensitive S.
tigecycline lend support to this hypothesis but are not conclusive
[12].
Although progression of infection occurred in many who  died,
an association between lack of clinical efﬁcacy and mortality is difﬁ-
cult to conclude owing to composite endpoints used in registration
trial designs. In addition, patients with the higher probability of
dying (e.g. increased APACHE II score), at least in the approved
indications, had similar clinical outcomes whether treated with
tigecycline or comparator. This was not the case for patients with
HAP, speciﬁcally VAP. Similar to the patient-level analyses, this sug-
gests that other variables such as infection type are important and
that there is a more complex explanation of mortality than simply
a lack of efﬁcacy.
The US Food and Drug Administration (FDA) presented their
own  analysis of the tigecycline mortality data [13]. The FDA results
and conclusions are in general agreement with our own, including
the timing of the deaths and the identiﬁcation of bacteraemia in
HAP, but not other indications. Increased cardiac events identiﬁed
by the FDA and observed in our own  analysis (not shown) appear to
be a progression of underlying infection and/or co-morbidities. A
recently completed tigecycline thorough QT study does not suggest
a direct cardiac toxicity and supports both our conclusion and that
of the FDA [13,14].
Despite the identiﬁcation of an all-cause mortality difference,
the post hoc meta-analyses of all-cause mortality data from the
tigecycline clinical trials, including our own, must be considered
exploratory and hypothesis-generating. First, all-cause mortality
was not a pre-speciﬁed powered endpoint, and no risk window
was speciﬁed a priori. Using a 30-day mortality window resulted
in a non-signiﬁcant risk difference but does not eliminate the
importance of the all-cause mortality signal. In addition, use of
the modiﬁed intention-to-treat safety population may not perfectly
reﬂect drug effects, since patients in many cases received limited
dosing.
Second, the study pooled all-cause mortality data from different
infectious disease indications. Both study-level and patient-level
analyses suggest clinical heterogeneity, which may  impact the
interpretation and generalisability of the results [15]. For exam-
ple, excess risk of mortality by individual infection type may  be
more important. Third, antibiotics are expected to reduce or pre-
vent complications of infectious diseases and therefore decrease
attributable mortality, not all-cause mortality [16].
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In conclusion, our analyses identiﬁed the all-cause mortality dif-
erence in the tigecycline clinical programme and this difference
as been conﬁrmed by other independent analyses. In general, the
eaths appear related to worsening or complications of the infec-
ion or underlying co-morbidities. Study-level and patient-level
nalyses have identiﬁed that patients in the HAP trial, particularly
hose with VAP with baseline bacteraemia, were at a higher risk
f clinical failure and mortality. Owing to the increase in antibiotic
esistance worldwide and the relative lack of available treatment
ptions [17], tigecycline remains an appropriate treatment option
or its approved indications. Ultimately, the choice of antibiotics
hould include a beneﬁt/risk assessment, with consideration of the
ndividual patient’s particular clinical situation.
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